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Background: Several types of T cells have been associated with the pathogenesis of unexplained recurrent
spontaneous abortion (URSA), including Th1/Th2/Th17/Tregs cell. It has been appreciated that immunotherapy with
paternal or third party lymphocytes is an effective method of treatment for URSA patients. The balance of Th1/Th2
cells could be maintained and an increase of Treg cells would be beneficial after immunotherapy; however, the
mechanism by which the Th17/Treg balance affects URSA has not yet been fully elucidated.
Methods: Here, we used flow cytometry, liquid chip technology and quantitative real-time PCR (qPCR) methods to
characterize Th17/Treg cell populations after immunotherapy. We found that after immunotherapy in URSA patients,
the percentage of Th17 cells decreased and the percentage of Treg cells in peripheral blood mononuclear cells
(PBMC) increased, as detected by flow cytometry.
Results: Immunotherapy may induce a decrease in the Th17/Treg ratio and the Treg bias, which may be beneficial
for the maintenance of pregnancy. The expression level of ROR gamma t, a transcription factor found in Th17 cells,
decreased and the expression of the Treg-specific transcription factor Foxp3 increased in peripheral blood as
detected by qPCR. Immunotherapy may induce a decrease in the ratio of ROR gamma t to Foxp3 and a Treg cell
bias, which would be beneficial for pregnancy maintenance. The secretion of the Treg-associated cytokine
TGF-beta, as well as Th2 cytokines, was increased in serum, while the secretion of Th17-associated cytokine IL-17A
and Th1 cytokine production was decreased. The Th1/Th2 cytokine ratio significantly decreased. Similarly, the
Th17/Treg ratio significantly decreased in the total patient after immunotherapy.
Conclusions: These results indicate that in patients with URSA, immunotherapy with mononuclear cells derived
from the baby’s father could affect both Th1/Th2 and Th17/Treg balance, and we found that the Th2 and Treg bias
would be beneficial for pregnancy, which may lead to a balancing of the Th17/Treg ratio in URSA patients after
immunotherapy.
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An estimated 1–3% of women have experienced three or
more consecutive miscarriages prior to 20 weeks gesta-
tion, and this is defined as recurrent spontaneous ab-
ortion (RSA) [1]. Unexplained recurrent spontaneous
abortion (URSA) affects approximately 50% of RSA pa-
tients, and it is largely associated with the failure of feto-
maternal immunologic tolerance. The embryo expresses
paternal antigens that are foreign to the mother and
therefore may be viewed as an allograft; in normal
pregnancy, the embryo is not rejected by the mother’s
immune system [2]. Literature indicates that altered im-
munity in URSA is dominated by what is known as the
Th1/Th2 hypothesis [3]. The emerging concept of the
Th17⁄Treg balance has challenged the conventional para-
digm of Th1⁄Th2 hypothesis [4,5]. Th17 and Treg T cells
have been described as two subsets that are distinct from
Th1 and Th2 cells with opposite effects on autoimmun-
ity and transplantation tolerance [6,7]. Lee SK et al. [8]
reported that the imbalance between Th17 and Treg
cells was correlated with the pathogenesis of URSA.
Several reports have suggested that the normal human
pregnancy is associated with an elevation of the immuno-
suppressive Treg subset, and Tregs were recognized to
play a crucial role in the maintenance of normal immune
tolerance [9-11]. Wang et al. [12] and our previous find-
ings [13] demonstrated that the percentage of Th17 cells
were higher in the peripheral blood of patients with
URSA, suggesting a potentially negative role of Th17
cells in the maintenance of pregnancy.
Since the 1980s, immunotherapy with paternal or
third-party lymphocytes has been an effective treatment
for URSA, and it effectively allows for the suppression of
the maternal immune responses to the allogeneic fetus
in vivo during pregnancy [14-18]. The mechanisms by
which immunotherapy works have not yet been fully
elucidated, but it may skew the balance of Th1/Th2 cells
in patients with URSA who undergo immunotherapy
[19-21]. Several studies have indicated that lymphocyte
immunotherapy significantly increased the proportion of
CD4+/CD25+ Treg cells in peripheral blood mono-
nuclear cells (PBMCs) in women with URSA, and it
ultimately improved pregnancy outcome [22]. Several re-
ports found that Th17 cells may play a vital role in
rejecting conceptus antigens and therefore may be detri-
mental for the maintenance of pregnancy. An abnormal
balance of Th17/Treg cells may exist in URSA [8,12,13].
However, the association between immunotherapy and
Th17 cells and the Th17/Treg balance has not yet been
fully elucidated.
In this study, we found a decrease in the proportion of
Th17 cells in PBMCs and decreases in the expression of
Th17-related cytokine IL-17A and Th17-related tran-
scription factor RORγt mRNA [23] in peripheral bloodafter immunotherapy with paternal or third party lym-
phocytes. Furthermore, an increased proportion of Tregs
in PBMCs as well as elevated expression of Treg-related
cytokine TGF-β and Treg-associated transcription factor
Foxp3 mRNA [24] were also detected in the peripheral
blood. We also found that the Th17/Treg cell ratio was
decreased and that the Treg bias improves pregnancy
outcome following immunotherapy. After analyzing suc-
cessful pregnancies that had undergone immunotherapy,
we found that the Treg cell bias contributed to the im-
provement of pregnancy outcome. Taken together, these
results help clarify the etiology of immunotherapy with
paternal or third party lymphocytes and provide a novel
target for the prevention or intervention of spontaneous
abortion via regulation of the Th17/Treg balance.
Methods
Patients
The study was conducted in compliance with the
Declaration of Helsinki and Ethics Committees on
Human Research of Anhui Provincial Hospital, an affili-
ation of the Anhui Medical University. This study had
the approval of the Ethics Committee of Anhui Province
Hospital; informed consent was obtained before samples
were collected (2010 Ethics 5th). All the subjects were
patients of the outpatient department of gynecology at
Anhui Province Hospital (Hefei, China) between May
2010 and May 2011. Through communication with all
couples, they agreed to participate in the study and
signed an informed consent form prior to enrollment.
This is a prospective study. Twenty patients who had
experienced at least three confirmed successive spontan-
eous early abortions (7–12 weeks of gestation) of unex-
plained etiology with one partner were recruited to
participate in the study. The mean ± SE deviation age
was 28.6 ± 0.15 (ranging from 25–37) years, and the me-
dian number of miscarriages was 4 (range, 3–7, and all
the women had natural conception). None of the partici-
pants had a genetic impairment, Mullerian anomaly,
hormonal deficiency, metabolic disorder, infectious dis-
ease, or autoimmune abnormalities, such as positive
antiphospholipid antibodies or lupus anticoagulant, in
our systemic workup. In addition, tests for thrombophi-
lic status, such as protein C activity, protein S activity,
and thrombin anti-thrombin III complex were routinely
performed for all patients (Details were showed in
Additional file 1: Table S1).
All patients were healthy except for their history of re-
current abortions and were negative for blocking anti-
bodies, which were identified by a one-way mixed
lymphocyte culture reaction (responder: patient, stimu-
lator: husband), according to previously reports. Berifly,
Lymphocytes were collected from heparinized blood via
Ficoll-Hypaque gradient centrifugation. The mitomycin
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cells of the patient were mixed and co-cultured in RPMI
1640 containing either pooled human AB serum or tested
serum for 6 days. After a pulse time of 18 hours cultured
with 3H-thymidine, the cultured cells were harvested and
the DNA synthesis was evaluated by liquid scintillation
counting. The blocking effect (BE) was calculated as fol-
lowing BE = (1-meancpm of culture in tested serum/
mean cpm of culture in AB serum)*100 (%).
Paternal or third-party lymphocytes immunization
Donor (husband or third party) lymphocytes were pre-
pared by Ficoll-Paque centrifugation; the cells were
washed three times with sterile saline and resuspended
in 1 ml at a concentration of 2–3 × 107 cells/ml. The
cells were administered three times intradermally at 3-
week intervals. We collected the blood after fourth
immunization (about 12 weeks after first immunization),
and all samples were collected at the same time point. In
this study, the lymphocyte immunization therapies were
performed every 3 weeks for four times, and then main-
taint the lymphocyte immunization therapy every 6 weeks.
Cell preparation
For Th17 analysis, human PBMCs were suspended at a
density of 2 × 106 cells/mL in complete culture medium
(RPMI 1640 supplemented with 100 μ/ml streptomycin,
100 u/ml penicillin, 2 mm glutamine and 10% heat-
inactivated fetal calf serum (Gibco, Invitrogen, CA,
USA)). The cell suspension was transferred to 24-well
plates. Then, cultures were stimulated with phorbol
myristate acetate (PMA, 50 ng⁄mL) plus ionomycin
(1 μg/ml) for 5–6 hr in the presence of monensin
(500 ng⁄mL; all from Alexis Biochemicals, San Diego,
CA, USA). Cells were grown in a 37°C incubator at 5%
CO2. After 5–6 hr of culture, the contents of the wells
were transferred to 5-mL sterile tubes. The cells were
then centrifuged at 350 g for 5 min. For Treg analysis,
PBMCs (100 μL) were aliquoted into tubes for further
staining.
Surface and intracellular staining
Cells were aliquoted into tubes and washed once in phos-
phate buffered saline (PBS). For Th17 analysis, the cells
were incubated with fluorescein isothiocyanate (FITC)
anti-human CD4 (eBioscience, San Diego, CA, USA) at
4°C for 20 min. For Treg analysis, the cells were incu-
bated with PerCP anti-human CD4 (eBioscience, USA)
and FITC anti-human CD25 (eBioscience, San Diego,
CA, USA) at 4°C for 20 min. After the surface staining,
the cells were then fixed and permeabilized with Perm/
Fix solution (Beckman Coulter) and were stained with PE
anti-human IL-17A (eBioscience) for Th17 detection
or PE anti-human Foxp3 (eBioscience, CA, USA) forTreg detection. All staining was performed according to
manufacturer’s protocols. Isotype controls were used to
enable correct compensation and confirm antibody spe-
cificity. Samples were analyzed using a FACS Calibur
flow cytometer and Cell Quest Pro software (Beckman
Coulter).
Quantitative real-time PCR (qRT-PCR)
The tissues were collected in RNase-free tubes and total
RNA was extracted using Trizol reagent (Invitrogen).
RNA samples were quantified with a NanoDrop™ 1000
Spectrophotometer (Thermo scientific) and electrophor-
esis. Briefly, the peripheral blood cells were homoge-
nized in Trizol reagent, and then chloroform was added
to the 1/5 volume of Trizol and mixed thoroughly. The
mixture was centrifuged at 12,000 g (4°C) for 15 min.
The supernatant was collected and mixed with isopropa-
nol at a ratio of 1:1 and incubation for 10 min and was
then centrifuged at 14,000 g (4°C) for 10 min. The
supernatant was removed and 100 μl 75% ethanol was
added to the tubes and mixed thoroughly. After centrifu-
gation at 8,000 g (4°C) for 5 min, the supernatant was
removed and the tubes were air-dried. cDNA was syn-
thesized using the prime ScriptTM 1st strand cDNA
synthesis kit according to the manufacturer’s instruc-
tions (Fermentas Thermo). Real-time quantification of
target mRNA was performed using a SYBR premix Ex
TaqTM II kit (Takara) according to the manufacturer’s
instructions. Briefly, amplification was performed in a
total volume of 10 μl, and each reaction contained 5 μl
SYBR REmis EX TaqTM, 0.4 μl forward and reverse
PCR primers, 0.2 μl ROX reference Dye II, 1 μl cDNA
and 3 μl ddH2O. The real time PCR program consisted
of an initial step of 10 s at 95°C, followed by 40 cycles of
denaturing at 95°C for 5 s and extension at 60°C for
31 s. All measurements were performed at least three
times. GAPDH was used as a housekeeping gene. The
following primer sequences were used: RORγt-forward,
5-ACC TCA CCG AGG CCA TTC AG-3 and reverse,
5-TAGG CCC GGC ACA TCC TAA C-3; Foxp3-
forward, 5-ATC TAC CAC TGG TTC ACA CGC AT-3
and reverse, 5-CTC CAC CCG CAC AAA GCA C-3;
GAPDH-forward, 5-GGT GTG AAC CAT GAG AAG
TAT GAC A-3 and reverse, 5-GTC CTT CCA CGA
TAC CAA AGT TGT-3.
Multiplex fluorochrome assay
The expression level of cytokines, such as interleukin
(IL)-6, IL-10, IL-17A, IL-23, tumor necrosis factor
(TNF), TGF-β and IFN-γ, were measured in serum sam-
ples, and Bio-Plex Human Cytokine Panel (Bio-Rad
Laboratories) was used according to the manufacturer’s
instructions. The human serum diluent kit (Bio-Rad La-
boratories) was employed for purification of the samples.
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was performed with a Luminex 100 instrument (Luminex
xMAP Technology, Austin). Acquisition conditions were
set with a minimum of 100 beads per region. All of the
raw data (median fluorescence intensity) from the bead
combinations tested were analyzed using StarStation
Software 2.3 (Applied Cytometry Systems). A five-
parameter curve fit was used to create each standard
curve to obtain the values of sample concentration. The
cutoffs for minimum detectable concentration for the
cytokines were as follows: 0.5 pg/mL (IL-6, IL-23),
0.6 pg/mL (IL-10, IFN-γ), 0.7 pg/mL (IL-17A) and
1.3 pg/mL (TNF). The specific antigen- and mitogen-
induced cytokine secretions were calculated by sub-
tracting the spontaneous background secretion.Statistical analysis
Statistical analysis was conducted with Student’s t test.
All data analyses were performed by SPSS statistical soft-
ware (version 13). Data are presented as the means ± SE.
A two-tailed p-value of <0.05 was considered to be
significant.Figure 1 The percentages of Th17 and Treg cells in peripheral blood
immunotherapy. The percentage of Th17 and Treg cells in peripheral bloo
patient population before and after immunotherapy, respectively. (a) The p
significantly decreased after immunotherapy (P < 0.01, paired t-test). Bar rep
E. The percentage of Treg cells in peripheral blood mononuclear cells signi
represents the frequency of CD4+/CD25bright/Foxp3+ cells and the means
mononuclear cells significantly decreased after immunotherapy (P < 0.01, p
after immunotherapy and values of means ± S.E. Representative CD4+/IL-17
immunology. Representative CD4+/CD25bright/Foxp3+ flow cytometry ploResults
Circulating Th17 Cells, Treg Cells, and the ratio of Th17/
Treg cells in patients with URSA after immunotherapy
The percentage of IL-17+/CD4+ in PBMC in the total
patient population with URSA before immunotherapy
was 2.73 ± 0.68%, and the percentage of this subset after
immunotherapy was 1.51 ± 0.29% (P < 0.01, paired t-test,
Figure 1). Thus, the percentage of Th17 cells signifi-
cantly decreased after immunotherapy compared with
that before immunotherapy (Figure 2). We quantitated
the percentage of Treg cells within the CD25bright cell
population because only these cells represent both fide
Treg in human [25,26]. As shown in Figure 3, the
percentage of Tregs (CD4+CD25brightFoxp3+ T cells) in
PBMC was significantly increased in patients with URSA
following (4.94 ± 1.38%) as compared with before (3.03 ±
0.91%) immunotherapy (P < 0.01, paired t-test, Figure 1).
Thus, the percentage of Treg significantly increased after
immunotherapy (Figure 2). The mean Th17/Treg ratio in
all patients with URSA before immunotherapy was 0.98
but dropped to 0.33 after immunotherapy (P < 0.05,
Figure 1). Therefore, the mean Th17/Treg ratio signifi-
cantly decreased after immunotherapy compared with themononuclear cells and the Th17/Treg ratio varied with
d mononuclear cells were detected by flow cytometry in the total
ercentage of Th17 cells in peripheral blood mononuclear cells
resents the CD4+/IL-17A+ cell frequency and values of the means ± S.
ficantly increased after immunotherapy (P < 0.01, paired t-test). Bar
± S.E. are shown. (b) The Th17/Treg ratio in peripheral blood
aired t-test). Bar represent Th17/Treg ratio in total patients before and
A + flow cytometry plots in patients are shown before (c) and after (d)
ts in patients are shown before (e) and after (f) immunology.
Figure 2 The change of Th17 and Treg cells in peripheral blood mononuclear cells and the Th17/Treg ratio varies in total patients
and patients with a successful pregnancy after immunotherapy. The detailed variation of CD4+/IL-17A + (a), CD4+/CD25bright/Foxp3+
(b) and Th17/Treg ratio (c) in each patient before and after immunotherapy is shown in line chart. The detailed variation of CD4+/IL-17A + (d),
CD4+/CD25bright/Foxp3 + (e) and Th17/Treg ratio (f) in each patient with a successful pregnancy after immunotherapy is shown in the
line chart.
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shown in Figure 3.Circulating Th17 cells, Treg cells, and the ratio of Th17
and Treg cells in URSA patient with successful
pregnancies following immunotherapy
To date, 13 of the 20 patients had recent pregnancies.
Of these 13 patients, the pregnancy continued in 11 pa-
tients (successful group) (83.3%), while the remaining 2
cases underwent repeated abortion (unsuccessful group).
Of the 11 patients with successful pregnancies, 8 pa-
tients delivered babies and the remaining 3 are still preg-
nant (their gestational weeks [Gw] are 20, 28 and 23).
The mean percentage of CD4+/IL-17+ T cells of the
successful group before immuno- therapy was 2.72% of
total PBMC, and the mean percentage after immuno-
therapy was 1.58% (Figure 3). The percentage of Tregs
(CD4+CD25brightFoxp3+ T cells) was significantly higher
in the successful group (5.19 ± 1.38%) after than before
(2.80 ± 0.95%, P < 0.01) immunotherapy (Figure 3). The
mean of the Th17/Treg ratio in the successful group be-
fore immunotherapy was 1.06, and the mean ratio after
immunotherapy was 0.32 (Figure 3).
Thus, in the successful group, the percentage of Th17
cells (Figure 2) was significantly lower and the percent-
age of Tregs (Figure 2) was significantly higher after im-
munotherapy. The ratio of Th17/Treg cells (Figure 2)
was significantly lower after immunotherapy.The cytokines measured in serum samples
The concentrations of Th1-type cytokines IFN-γ and
TNF-α were significantly decreased in the serum of
patients with URSA before immunotherapy (1.97 ± 0.69
and 4.66 ± 1.32 pg/ml) than after immunotherapy (1.03 ±
0.37 and 2.28 ± 0.96 pg/ml). The concentration of Th2-
type cytokine IL-10 before immunotherapy was 6.32 ±
2.46 and after immunotherapy was 10.87 ± 4.32 pg/ml,
which was a significant increase. Th17-type cytokines
such as IL-6 and IL-23 were significantly decreased after
immunotherapy; before immunotherapy, IL-6 and IL-23
were 1.60 ± 0.49 and 17.94 ± 9.76 pg/ml, respectively, and
after immunotherapy were 0.89 ± 0.34 and 7.78 ± 3.43
pg/ml. Additionally, the concentration of TGF-β was
significantly higher after immunotherapy (3909.05 ±
1248.35 pg/ml) versus before (2469.83 ± 1058.71 pg/ml).
IL-17A (Fig. 4f ) was significantly decreased after im-
munotherapy (1.57 ± 0.78 pg/ml) compared with that be-
fore immunotherapy (4.32 ± 1.40) (P < 0.01, paired t-test).
As shown in Figure 4.
Th1/Th2 balance in patients with URSA who under-
went immunotherapy had been reported, and we also
found that there may be a unique balance between Th1-
type cytokines, such as IFN-γ, and Th2-type cytokines,
such as interleukin IL-10, as shown in Figure 5. The con-
centration of Th17-type cytokine IL-17A was significantly
lower and Treg-type cytokine TGF-β was significantly
higher after immunotherapy compared with concentration
before immunotherapy. The ratio of Th17/Treg cytokines
Figure 4 The interleukins/cytokines were detected by multiplex fluorochrome assay in serum samples from the total patients before
and after immunotherapy. (a) The content of TGF-β, IL-10, IFN-γ, TNF-α, IL-17A, IL-23, and IL-6 in serum varied before and after immunotherapy.
The detailed variation of TGF-β (b), IL-10 (c), IFN-γ (d), TFN-a (e), IL-17A (f), IL-23 (g), and IL-6 (h) in each patient before and after immunotherapy
is shown in the line chart.
Figure 3 The percentage of Th17 and Treg cells in peripheral blood mononuclear cells and the Th17/Treg ratio varies in patients
with a successful pregnancy after immunotherapy. The percentage of Th17 and Treg cells in peripheral blood mononuclear cells were
detected by flow cytometry in patients with successful pregnancy after immunotherapy. To date, 13 of the 20 patients have become newly
pregnant. Of the 13, the 11 patients did not miscarry (successful group). (a) The percentage of Th17 cells in peripheral blood mononuclear cells
significantly decreased after immunotherapy. The percentage of Treg cells in peripheral blood mononuclear cells significantly increased after
immunotherapy (P < 0.01, paired t-test). Bar represents the CD4+/IL-17A + cell frequency and the means ± S.E. are indicated (b) The Th17/Treg
ratio in peripheral blood mononuclear cells significantly decreased after immunotherapy (P < 0.01, paired t-test). Bar represent the frequency of
CD4+/CD25bright/Foxp3+ cells and the means ± S.E. are indicated. Representative CD4+/IL-17A + flow cytometry plots from patients with
successful pregnancies were shown before (c) and after (d) immunotherapy. Representative CD4+/CD25bright Foxp3+ flow cytometry plots
from patients with successful pregnancies were shown before (e) and after (f) immunotherapy.
Wu et al. Reproductive Biology and Endocrinology 2014, 12:74 Page 6 of 9
http://www.rbej.com/content/12/1/74
Wu et al. Reproductive Biology and Endocrinology 2014, 12:74 Page 7 of 9
http://www.rbej.com/content/12/1/74was significantly lower after immunotherapy as compared
with before immunotherapy (Figure 5).
The mRNA expression of RORγt and FOXP3
The most important transcription factor for the differen-
tiation of naïve T cells into Tregs is the forkhead box P3
(Foxp3) [24]. Similarly, retinoic acid–related orphan re-
ceptor t (RORγt) [23] is a crucial transcription factor for
the development of Th17 cells. The mRNA expression
of Foxp3 was significantly increased after immunother-
apy. Meanwhile, the mRNA expression of ROR γ t was
significantly decreased after immunotherapy, as shown
in Figure 6.
Discussion
Several studies characterizing immunotherapy in URSA
patients reported that the outcome of subsequent preg-
nancies was apparently improved by injection of paternal
or a third party’s leukocytes [14-18], although the findings
of Ober C et al. [27] suggested this treatment is ineffective.
The efficacy of immunotherapy might be related to the
immune response by allogeneic lymphocytes and might
not be simply a placebo effect. From a worldwide meta-
analysis study, it has been indicated that immunization
may be highly effective, although only for a small number
of patients with URSA [28,29]. In our center, 80-90% of
URSA patients who underwent immunotherapy success-
fully delivered a baby. Although immunotherapy was
considered possibly efficacious, the underlying mecha-
nisms have not yet been fully elucidated.
The Th1⁄Th2 balance in circulating T cells has been re-
ported to be shift in favor of Th2 dominance during nor-
mal pregnancy, whereas the Th1 dominance has been
found to be associated with reproductive failures such as
URSA [30,31]. Although Wilczynski JR et al. reported
that Th1/Th2 bias was not correlated with subsequent
pregnancy success in the patients who accepted paternal
lymphocyte immunization (PLI) [32], most related stud-
ies suggested that Th1⁄Th2 imbalance plays an important
role in URSA and is a target for treatment of PLIFigure 5 The ratio of IFN-γ/IL-10, and IL-17A/TGF-βvaried in total pat
ratio of IFN-γ/IL-10 (a), and IL-17A/TGF-β (b) in each patient is shown in th[19-21]. Tomokazu Yokoo et al. [20] and Qiu L et al.
[21] reported that immunotherapy with the husband’s
mononuclear cells could induce a dominant state of Th2
cells in URSA patients. Th1 type cytokines, such as
TNF-α and IFN-γ, are detrimental to pregnancy at high
concentrations [21]. In the present study, we also found
that TNF-α and IFN-γ were significantly decreased after
immunotherapy. Additionally, Th2-type cytokine IL-10
was significantly increased after immunotherapy [21].
The induction of Th2 bias might be correlated with the
successful continuation of pregnancy in patients with
URSA who undergo immunotherapy with lymphocytes
derived from the baby’s father.
Several studies support our findings that the propor-
tion of CD4+CD25+ Treg cells in peripheral blood lym-
phocytes was significantly lower in URSA women than
in normal (non-pregnant) control subjects, which sug-
gests that CD4+CD25+ Treg cells might contribute to
the mechanisms mediating maternal immune tolerance
of conceptus antigens, and therefore, Treg cells might
contribute to the maintenance of pregnancy [25,26]. The
reciprocal developmental pathway for the generation
and the opposing effects of Th17 and Treg cells may
affect the balance between these cell subsets in patients
with URSA [4,5,12]. Investigators suggested a potentially
deleterious role for Th17 cells in pregnancy [12,13]. Our
previous data [13] also implicated that the imbalance be-
tween Th17 and Treg cells may play an important role
in the pathogenesis of URSA. Hui Yang et al. [22] dem-
onstrated that lymphocyte immunization significantly in-
creased the percentage of Tregs in peripheral blood in
women with URSA, contributing to improved pregnancy
outcome. The data suggested that Tregs may be a novel
target in URSA therapy.
Progesterone is required for the establishment and main-
tenance of pregnancy, and the link between progesterone
and the immune system is also established. Several reports
suggested that the immunological effects of progesterone
are mediated by progesterone-induced blocking factor
(PIBF). Through the Il-4 receptor, PIBF induces a Th2-ients before and after immunotherapy. The detailed variation of the
e line chart.
Figure 6 The expression of FOXP3 and RORγT mRNA varied
before and after immunotherapy in URSA patients. (a) The
mRNA level of FOXP3 was increased significantly in the total
patients after immunotherapy (P < 0.01, students t-test). Bar
represent the values of 2-ΔΔCt. (b) The mRNA level of RORγT was
decreased significantly in the total patients after immunotherapy
(P < 0.01, students t-test). Bar represents the values of 2-ΔΔCt.
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IL-3, IL-4 and IL-10 [33,34]. The treatment of progester-
one in Th1-like T cells led to increased expression of IL-4
mRNA and production [35]. These results indicated that
PIBF might play a role in regulation of Th1/Th2 balance
during lymphocyte immunotherapy of URSA.
In present study, we first analyzed Th17 cells, Treg cells,
and the Th17/Treg balance in URSA patients following
lymphocyte immunization. Subsequently, we detected a
significant decrease in Th17 cells, a significant increase in
Treg cells in PBMCs, and a significant decrease in the
Th17/Treg ratio in URSA patients after immunotherapy.
Furthermore, this phenomenon was reinforced by the
demonstration that URSA patients could have a successful
subsequent pregnancy after immunization therapy. It has
been reported that increased IL-23 or IL-6 production and
decreased TGF-β production might cause an increase in
Th17 cells and a decrease in Treg cells in the uterus
[10,12,36,37]. We detected the Th17-related soluble cyto-
kines, such as IL-6, IL-17A, and IL-23 in serum, and
found that levels of these cytokines were significantly de-
creased after immunotherapy. Similarly, levels of Treg-
associated cytokines IL-10 and TGF-β were significantly
higher after immunotherapy. Tregs exert their function
partly through secretion of the anti-inflammatory cyto-
kines IL-10 and TGF-β. Additionally, TGF-β can promote
Foxp3 expression by inducing Treg differentiation from
CD4+/CD25 + T cells [38-42]. This is in accordance our
data that the expression of Foxp3 mRNA was higher after
immunotherapy compared with before immunotherapy.
Conversely, the expression of ROR γ t mRNA was lower
after immunotherapy.Conclusions
In this context, we initially analyzed the Treg cells bias
against Th17 cells and whether it may play a role in the
maintenance of pregnancy. It is possible that immunother-
apy affects the Th17 and Treg cell balance in patients.
Therefore, up-regulation of the Treg population and
down-regulation of the Th17 population might contribute
to the outcome of pregnancy. The data suggest that regu-
lating the balance of Th17/Treg may be a novel target in
URSA therapy. The limitation of this study is the number
of samples is small, and further study is required.
Additional file
Additional file 1: Table S1. Clinical characteristics of the patients.
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